Cell therapy weekly: new CAR-T therapy shows promise against neuroblastoma

Written by RegMedNet

This week: researchers have developed a novel CAR-T therapy that has shown promising early results against neuroblastoma, Novartis has secured a worldwide license for Mesoblast’s remestemcel-L cell therapy, a new gene therapy approach has been developed for dominant optic atrophy, and Mustang Bio and Minaris Regenerative Medicine have signed an agreement to enable technology transfer and GMP clinical manufacturing of a lentiviral gene therapy for X-linked severe combined immunodeficiency. The news highlights: New CAR-T therapy shows promise against neuroblastoma Novartis secures global license to Mesoblast’s cell therapy for acute respiratory distress syndrome Novel gene therapy approach developed for dominant optic...

To view this content, please register now for access

It's completely free